News & Updates

First-line immunotherapy treatment with atezolizumab – a PD-L1 inhibitor – offers a survival advantage over single-agent chemotherapy in patients with advanced non-small cell lung cancer (NSCLC) who are ineligible for platinum doublets in the phase III IPSOS trial.

Tumour-infiltrating lymphocyte therapy significantly improved progression-free survival (PFS) in patients with advanced melanoma compared with standard-of-care treatment with ipilimumab, according to the M14TIL trial presented at ESMO 2022.

Vonoprazan may be as effective as pantoprazole in reducing the risk of ulcers or bleeding following endoscopic variceal ligation (EVL) in patients with portal hypertension, according to a small study from Egypt presented at the United European Gastroenterology Week (UEG 2022).

Patients with normal, instead of impaired, renal function tend to benefit more from the combination therapy ticagrelor plus aspirin than clopidogrel plus aspirin, reveals a study.

Biomarkers such as C-reactive protein (CRP) and procalcitonin are robust predictors of serious bacterial infections (SBIs) and invasive bacterial infections (IBIs), respectively, in febrile infants, results of a Singapore study have shown.

A deficiency in vitamin D levels appears to increase the risk of death in adults, suggests a study.

The use of an exhalation delivery system with fluticasone (EDS-FLU) significantly reduces acute exacerbations of chronic rhinosinusitis (CRS), which may help drive down the need for antibiotics and prevent antibiotic resistance, in the ReOpen1 and 2 randomized controlled trials.